Jubilant Pharmova Ltd

Jubilant Pharmo Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jubilant Pharmova Ltd

₹ 1,170 -0.35%
02 Jun - close price
jubl.com BSE: 530019 NSE: JUBLPHARMA
About

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]

Key Points

Business Segments & Revenue Contribution 9MFY24[1][2]
a) Radiopharma (~44%): Radiopharmaceuticals (including radiopharmacies)The company is the #3 radiopharmaceutical manufacturer in the US and has the #2 network in the US with 46 radiopharmacies. In 9MFY24, sale of Mertiatide, Sulfur colloid) and Ruby-Fill did very well. RUBY-FILL is a cardiac imaging product. Company plans to maintain its leadership position in North America.[3]

Website BSE NSE
  • Market Cap ₹ 18,656 Cr.
  • Current Price ₹ 1,170
  • High / Low ₹ 1,310 / 617
  • Stock P/E 761
  • Book Value ₹ 146
  • Dividend Yield 0.43 %
  • ROCE 2.90 %
  • ROE 1.04 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 275%

Cons

  • Stock is trading at 8.04 times its book value
  • The company has delivered a poor sales growth of -25.0% over past five years.
  • Company has a low return on equity of 1.49% over last 3 years.
  • Earnings include an other income of Rs.88.4 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
241 205 223 183 200 217 186 175 206 167 166 196 217
220 209 216 185 198 213 186 176 194 166 172 185 191
Operating Profit 20 -4 7 -2 2 4 1 -1 12 1 -6 11 26
OPM % 8% -2% 3% -1% 1% 2% 0% -0% 6% 1% -4% 6% 12%
7 10 106 8 14 16 18 19 50 8 44 18 18
Interest 3 3 4 6 6 6 7 8 8 8 8 7 7
Depreciation 9 9 11 12 11 11 12 12 13 13 13 13 13
Profit before tax 15 -6 98 -11 -1 2 0 -2 42 -11 17 9 24
Tax % 32% -20% 7% -47% 2,467% 17% 300% 4% 22% -9% 37% 39% 42%
10 -5 92 -6 -31 2 -0 -2 32 -10 10 5 14
EPS in Rs 0.66 -0.33 5.76 -0.37 -1.93 0.12 -0.03 -0.15 2.04 -0.64 0.66 0.33 0.85
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
3,666 3,172 2,656 2,491 3,306 3,439 3,140 2,710 726 810 785 746
3,076 2,890 2,344 2,173 2,765 3,112 2,765 2,282 719 807 767 714
Operating Profit 590 282 312 318 541 326 375 427 6 3 18 32
OPM % 16% 9% 12% 13% 16% 9% 12% 16% 1% 0% 2% 4%
-198 305 62 52 45 72 168 48 126 138 102 88
Interest 285 233 201 174 135 129 136 102 11 18 30 30
Depreciation 175 107 87 81 83 86 107 100 37 43 48 53
Profit before tax -68 246 86 115 368 183 299 273 85 79 42 38
Tax % -101% 17% 16% 31% 28% 20% -7% 21% 5% 37% 24% 49%
1 205 73 79 263 148 321 214 80 50 32 19
EPS in Rs 0.05 12.88 4.58 4.97 16.54 9.27 20.16 13.46 5.05 3.13 1.98 1.21
Dividend Payout % 5,652% 23% 65% 60% 18% 49% 25% 37% 99% 159% 252% 414%
Compounded Sales Growth
10 Years: -13%
5 Years: -25%
3 Years: 1%
TTM: -5%
Compounded Profit Growth
10 Years: -4%
5 Years: -40%
3 Years: -33%
TTM: -24%
Stock Price CAGR
10 Years: 23%
5 Years: 21%
3 Years: 44%
1 Year: 70%
Return on Equity
10 Years: 6%
5 Years: 4%
3 Years: 1%
Last Year: 1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 15 16 16 16 16 16 16 16 16 16 16 16
Reserves 1,717 1,929 1,998 2,027 2,233 2,324 2,591 1,267 2,423 2,399 2,359 2,302
3,314 2,279 1,808 1,698 1,424 1,702 2,013 504 183 346 380 343
1,604 963 507 651 951 821 814 58 274 248 237 248
Total Liabilities 6,651 5,188 4,329 4,391 4,625 4,864 5,433 1,845 2,896 3,008 2,992 2,910
2,151 1,446 1,415 1,421 1,438 1,491 1,865 127 637 687 711 699
CWIP 242 20 36 65 115 284 59 0 35 47 37 19
Investments 2,006 1,766 1,709 1,710 1,706 1,764 1,764 1,646 1,646 1,657 1,657 1,657
2,251 1,955 1,169 1,195 1,365 1,325 1,746 71 578 617 587 535
Total Assets 6,651 5,188 4,329 4,391 4,625 4,864 5,433 1,845 2,896 3,008 2,992 2,910

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
549 286 164 419 558 182 317 608 -4 -65 143 136
-194 1,319 522 -43 -127 -285 -198 178 93 31 -40 -2
-361 -1,647 -784 -338 -470 85 -41 -782 -107 22 -78 -157
Net Cash Flow -6 -42 -98 38 -40 -18 78 5 -18 -12 25 -24

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 53 37 47 57 54 51 49 0 66 85 90 101
Inventory Days 135 97 119 127 120 87 142 0 355 276 258 308
Days Payable 110 96 91 136 154 106 134 174 145 152 195
Cash Conversion Cycle 77 38 75 47 21 32 58 0 247 216 196 213
Working Capital Days -51 63 44 48 27 44 83 -2 127 154 137 123
ROCE % 9% 6% 7% 7% 14% 8% 10% 12% 4% 4% 3% 3%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
50.68% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67% 50.67%
23.47% 23.06% 23.38% 23.22% 23.20% 23.20% 20.29% 19.06% 19.50% 17.94% 16.96% 17.23%
0.62% 1.60% 1.62% 1.62% 1.63% 1.64% 2.89% 3.77% 4.06% 5.66% 6.99% 7.05%
0.00% 0.00% 0.00% 1.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
25.17% 24.59% 24.20% 23.11% 23.91% 23.89% 25.56% 25.91% 25.18% 25.17% 24.82% 24.48%
0.07% 0.07% 0.13% 0.13% 0.59% 0.59% 0.58% 0.58% 0.58% 0.56% 0.56% 0.56%
No. of Shareholders 1,09,4101,05,6321,00,21297,93593,37589,37686,58892,26481,99289,4561,02,44296,526

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls